Comment on

• Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.

  Cooper LJ, Ausubel L, Gutierrez M, Stephan S, Shakeley R, Olivares S, Serrano LM, Burton L, Jensen MC, Forman SJ, DiGiusto DL. Cooper LJ, et al. Cytotherapy. 2006;8(2):105-17. doi: 10.1080/14653240600620176. Cytotherapy. 2006. PMID: 16698684
• Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.

  Watanabe N, Narita M, Yokoyama A, Sekiguchi A, Saito A, Tochiki N, Furukawa T, Toba K, Aizawa Y, Takahashi M. Watanabe N, et al. Cytotherapy. 2006;8(2):118-29. doi: 10.1080/14653240600620200. Cytotherapy. 2006. PMID: 16698685
• Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma.

  Wu JY, Ernstoff MS, Hill JM, Cole B, Meehan KR. Wu JY, et al. Cytotherapy. 2006;8(2):141-8. doi: 10.1080/14653240600620218. Cytotherapy. 2006. PMID: 16698687